In a recent study, researchers used xMAP® Technology to design a multiplex assay from two separate immunogenicity assays to simultaneously identify and isotype ADAs in humans who received Humira®, a TNF inhibitor with a well-documented immunogenicity profile that is commonly used to treat rheumatoid arthritis and other inflammatory disorders.
Multiplex Technology Optimizes Traditional Immunogenicity Testing
